Journal of pediatric endocrinology & metabolism : JPEM · 2010
The relationship of insulin secretion and GAD65 antibody levels at diagnosis on glycemic control in type 2 diabetes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gumus Pinar, Gomez Ricardo, Vargas Alfonso, Chalew Stuart
Аннотация
OBJECTIVE: To determine if pretreatment insulin and C-peptide levels together with antibody status are predictive of HbAlc levels before and during therapy in obese African-American youth with type 2 diabetes.
METHODS: Records of African-American patients with clinical diagnosis of type 2 diabetes were retrospectively analyzed. Insulin, C-peptide, blood glucose, HbA1c and islet autoantibodies at diagnosis were recorded. These variables were compared with HbA1c levels during therapy.
RESULTS: Eight of 45 patients were islet autoantibody positive. There was no difference in age, Body Mass Index z-score, insulin, C-peptide, glucose or HbAlc levels between antibody positive or negative patients. Insulin (r = -0.45, p < 0.01 n=45) and C-peptide (r = -0.59, p < 0.001, n=36) were correlated with HbA1c at diagnosis but not during therapy.
CONCLUSIONS: Higher insulin levels were associated with lower HbA1c at presentation but not during therapy. Antibody status was not associated with differences in insulin, C-peptide levels or HbAlc level.
METHODS: Records of African-American patients with clinical diagnosis of type 2 diabetes were retrospectively analyzed. Insulin, C-peptide, blood glucose, HbA1c and islet autoantibodies at diagnosis were recorded. These variables were compared with HbA1c levels during therapy.
RESULTS: Eight of 45 patients were islet autoantibody positive. There was no difference in age, Body Mass Index z-score, insulin, C-peptide, glucose or HbAlc levels between antibody positive or negative patients. Insulin (r = -0.45, p < 0.01 n=45) and C-peptide (r = -0.59, p < 0.001, n=36) were correlated with HbA1c at diagnosis but not during therapy.
CONCLUSIONS: Higher insulin levels were associated with lower HbA1c at presentation but not during therapy. Antibody status was not associated with differences in insulin, C-peptide levels or HbAlc level.